Clinical Trials Browser

Interventional × Hodgkin Disease × umbralisib × Clear all

NCT03776864 2023-05-03

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 2 Terminated

6 enrolled 8 charts

Hodgkin Disease

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Phase 1/2 Terminated

14 enrolled 9 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT02164006 2019-10-02

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Phase 1 Completed

Hodgkin Disease